Sector News

Sorin Group Signs Merger Agreement with Cyberonics

March 25, 2015
Life sciences
(BUSINESS WIRE) – Sorin S.p.A., a global medical device company and a leader in the treatment of cardiovascular diseases, is pleased to announce that Sorin and Cyberonics Inc. in furtherance of the merger plan unanimously approved by their boards of directors, as disclosed in the joint statement of 26 February 2015, have signed today the relevant definitive merger agreement. The transaction remains subject to certain conditions including, without limitation: approval by both Sorin and Cyberonics’ shareholders, the receipt of required antitrust and regulatory clearances, and other customary closing conditions.
 
The combination of Sorin and Cyberonics will create a new premier global medical technology company. This merger is expected to drive significant value for shareholders by leveraging combined strengths, capturing new opportunities and creating new solutions to benefit patients and healthcare professionals alike and is particularly exciting for employees, who will be able to share technical expertise and innovate faster.
 
Sorin will provide further updates as the process progresses and relevant documents are available at www.sorin.com.
 
Source: Sorin Group

comments closed

Related News

February 25, 2024

Pharma CFOs need R&D vigilance in tough economic times

Life sciences

As inflation, high interest rates and a tight investment environment continue to create headaches, 72% of CFOs said economic volatility poses the same or greater risk to their business this year compared to 2023 in a recent survey from BDO — and there are more changes afoot.

February 25, 2024

Agilent CEO Mike McMullen to retire, succeeded by lab services head

Life sciences

McMullen, who’s also currently president of Agilent, is set to abdicate both roles on May 1, according to an announcement the company put out Wednesday afternoon. From there, McMullen will spend a few months serving as an advisor to Agilent and to his successor until his retirement becomes final on Oct. 31.

February 25, 2024

AstraZeneca completes Gracell Biotechnologies acquisition for $1.2bn

Life sciences

AstraZeneca has concluded its acquisition of China-based clinical-stage biopharmaceutical company Gracell Biotechnologies for $1.2bn. The acquisition, initially agreed in December 2023, positions Gracell as a wholly owned AstraZeneca subsidiary with operations continuing in the US and China.

How can we help you?

We're easy to reach